Navigation Links
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
Date:5/8/2008

Dana-Farber and Colorado Treating Patients with ENMD-2076

ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that Dana-Farber Cancer Institute has joined the University of Colorado Cancer Center in conducting a Phase 1 study of ENMD-2076 in advanced cancer patients. Dr. Geoffrey Shapiro, Dana-Farber Cancer Institute, and Dr. Wells Messersmith, University of Colorado Cancer Center, will serve as co-principal investigators for the study.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Safety and tolerability of orally administered ENMD-2076 in refractory cancer patients will be assessed in this Phase 1 study. A secondary objective for the study will be to determine a dose-dependent response to treatment with ENMD-2076 through the evaluation of pharmacokinetic parameters.

ENMD-2076 is a novel, selective kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to the promotion of cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways, resulting in both antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple preclinical models, including tumor regression in breast, colon, and leukemia models. Importantly, ENMD-2076 is an oral agent that has shown an acceptable toxicity profile in preclinical studies without cardiovascular toxicity.

Carolyn F. Sidor, MD, MBA, EntreMed Vice President and Chief Medical Officer commented on the study, "Both clinical trial sites are now enrolling and treating patients with our selective kinase inhibitor. We believe that this product candidate has substantial potential as both a single agent and in
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... (PRWEB) March 05, 2015 North ... Pierre Noel, M.D., Professor of Medicine, Mayo Clinic ... Company’s Board of Directors. , Entegrion’s ... extremely fortunate to have Dr. Noel, a distinguished ... healthcare organization, join Entegrion’s Board. His expertise in ...
(Date:3/5/2015)... e2b teknologies , a premier Sage ERP ... today announced a leading independent multi-specialty physician group practice ... the latest version of Sage 100 ERP . ... kind in the region, the organization has an extensive ... and data accessibility are paramount to their ongoing success. ...
(Date:3/4/2015)... , March 4, 2015 The UPMC ... its 2015 Fellows in the Emerging Leaders in Biosecurity ... future leaders in the field of biosecurity, UPMC has ... from a wide array of backgrounds, including biological science, ... sector. "With the vision and support ...
(Date:3/4/2015)... 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the ... a collaborative research program with Emerald Logic, ... Collective Evolution Technology (FACET), Emerald Logic analyzed ... obtained from each of 798 patients who ... trials ASSERT, SUSTAIN and ASSURE. The objective ...
Breaking Biology Technology:Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... A Milestone Reached to Commercialize Leading OAB Drug ... /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ) ... Clinical Trial Application ("CTA") for Enablex(R),(Darifenacin) was officially ... CTA acceptance is a key SFDA requirement prior ...
... Grant from Otsuka ... America Pharmaceutical, Inc., ROCKVILLE, Md., May 6 ... individual,as the recipients of the fifth annual APF Awards for Advancing ... Benefit in,Washington, D.C. Each organization or individual was presented a plaque,along ...
... Biomatrica, the leader in room,temperature biological sample stabilization, ... Vice President of Sales and Marketing.,Biomatrica,s interim Vice President ... part of the company and will continue to serve ... Dowling brings fourteen years of sales and marketing experience ...
Cached Biology Technology:BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial 2BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial 3American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 2American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 3American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 4American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 5Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing 2
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of the "Global Biometrics Market Forecast and ... The market for biometric authentication systems is ... 14% till 2020 The driving forces ... security needs, government projects and constant development in ...
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:2/24/2015)... Feb. 24, 2015 This report analyzes the worldwide ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle East ... estimates and forecasts are provided for the period 2013 through ... markets. Market data and analytics are derived from primary and ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Personal Data Protection Company Launches New Product 2World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11
... the western world, but new therapies based on stem cells ... held back however by the difficulty testing new therapies on ... value owing to differences in structure and activity. The only ... create computerised in-silico models that simulate the real heart and ...
... ocean floors, earths system of mid-ocean ridges plays a pivotal ... movements to heat flow from the interior, and the chemistry ... late 1970s that scientists discovered the existence of vast plumbing ... it, then spit it back out from seafloor ventsa process ...
... Methadone is a possible cause of sudden cardiac death even ... primarily for relief of chronic pain or drug addiction withdrawal, ... suggests. The studys findings, described in the January 2008 ... an evaluation of all sudden cardiac deaths in the greater ...
Cached Biology News:The construction of heart modelling leads path to new therapies 2The construction of heart modelling leads path to new therapies 3Quakes under Pacific floor reveal unexpected circulatory system 2Quakes under Pacific floor reveal unexpected circulatory system 3Methadone even at therapeutic levels can kill 2Methadone even at therapeutic levels can kill 3
Useful for determination of glucose and ATP. Packaging: Package sizes are based on hexokinase units. Preparation Unit Definition: One unit will phosphorylate 1.0 mol of D -glucose per min at pH ...
... Physical form: Lyophilized powder ... Preparation Unit Definition: One ... of 2-phosphoglycerate to phospho(enol)pyruvate ... at 25 C. Chem ...
SCCRO (S-17)...
Packaging: 6 bottles for 1 l ready-to-use-solution ID clarifier: ready-to-use solution ...
Biology Products: